Exploring a new therapeutic strategy for refractory eosinophilic airway inflammation by eosinophil peroxidase antibody

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07949
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Kansai Medical University
• Principal Investigator: KOBAYASHI Yoshiki 関西医科大学, 医学部, 講師 (10375298)
• Co-Investigator(Kenkyū-buntansha): 神田 晃 関西医科大学, 医学部, 准教授 (70375244)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 好酸球ペルオキシダーゼ抗体 / 好酸球性ムチン

Outline of Final Research Achievements

We focused on the formulation (defect in degradation) of eosinophilic mucin as one of mechanisms of refractory eosinophilic airway inflammation. Autoantibodies against eosinophil peroxidase (EPX Ab) are located in eosinophilic mucin, which may be involved in defect in degradation of mucin and activation of eosinophils. Neutralization of EPX Ab by low dose of EPX enhance degradation of mucin, indicating that it has the potential to be a new therapeutic strategy for refractory eosinophilic airway inflammation.

Free Research Field

気道炎症

Academic Significance and Societal Importance of the Research Achievements

好酸球性ムチンの気道局所への蓄積は、喘息・好酸球性副鼻腔炎などの難治性好酸球性気道炎症において治療抵抗性の主要な原因となっている。自己抗体EPX抗体がムチン中に存在し、好酸球の活性化とムチンの分解異常に関与すること、EPX抗体の中和がムチンの分解に有効であることがわかり、病態解明および新しい治療薬開発の一助となる可能性がある。